Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma

Fig. 5

Antigen-specific lysis by receptor-transfected γ/δ T cells of human melanoma cells. ZA-activated γ/δ T cells (left panels; closed symbols), OKT3-activated PBMC (a + b; right panels; closed symbols), OKT3-stimulated MACS-isolated CD8+ T cells (a + b; right panels; open symbols), and OKT3-stimulated MACS-isolated γ/δ T cells (a + b; left panels; open symbols) were obtained as described above (Fig. 1). Following 10 days of expansion, untouched γ/δ T cells were isolated from an aliquot of stimulated cells via negative selection using the TCR γ/δ T Cell Isolation Kit (c + d, right panels). Cells were electroporated as described above (Fig. 2). Mock-electroporated T cells (a + b; dotted lines; mock) served as controls. After over-night culture, the cytolytic capacity of receptor-transfected T cells towards human tumor cell lines was examined at indicated effector to target ratios in a standard 4–6 h chromium release assay. The percentage of lysed cells was calculated. Data are presented as means ± SEM derived from 4 to 7 independent experiments (a + b) or 3 independent experiments (c + d), each performed in technical triplicate. P-values calculated by unpaired Student’s t-test are presented in Additional file 1: Table S5 for a + b and in Additional file 1: Table S6 for c + d. a + c gp100 TCR-transfected T cells were co-incubated with human melanoma cell lines Mel525, A375M, and gp100-peptide pulsed A375M. b + d The human lymphoma cell line T2.A1 and the human melanoma cell lines Mel526 and A375M served as targets for MCSP CAR-RNA-transfected T cells

Back to article page